CLRB 2,16$

CRL131 Phase 2 Studie bald mit Ergebnissen

https://www.cellectar.com/product-pipeline

• Cash 13 Mio. $
  
• MK 11 Mio. $ (zum 31.12.18)
  
• Verlust 15 Mio. $ (in 2018)
  
• pro Quartal ~4 Mio. $
  
• Watchlist
  

https://investor.cellectar.com/press-releases/...-year-ended-december

 

• FDA Fast Track Designation für CRL 131
  
• Phase 1 Studiendaten für CRL 131
  

https://www.contractpharma.com/contents/...t-track-for-clr-131-in-mm/

https://investor.cellectar.com/press-releases/...-rate-in-cohort-6-of

 

https://www.nasdaq.com/de/symbol/clrb/real-time  

10 Mio. $ Offering

https://investor.cellectar.com/press-releases/...-0-million-financing

 

gestern nicht gekauft! Erst nen schönen Anstieg mit Rekordvolumen und dann eine KE. Ja, einfach mal den Allzeitchart bei den Amis anschauen!

https://www.nasdaq.com/de/symbol/clrb/real-time  

https://www.nasdaq.com/de/symbol/clrb/real-time  

https://old.nasdaq.com/de/symbol/clrb/real-time  

https://www.globenewswire.com/news-release/2019/...gy-Conference.html  

für CLR 131

https://seekingalpha.com/news/...eed_news_all&utm_medium=referral
 

20 Mio. $ Offering

https://investor.cellectar.com/press-releases/...ricing-of-20-million

 

Heute steigen gefühlt alle Biotechs zweistellig.....nur Cellectar schmiert ab. Unschön.  

über 60% seit Anfang Juni  

aber hier

 

Ich dachte die haben einen Geldspeicher wie Dagobert. Vermutlich nur Fakenews wie bei Donald.

Gruß Wilbär.

Offering

Verwunderlich das CLRB nicht stärker in Richtung des Angebotspreises vei 1,35$ fällt. Alles in allem sind das natürlich miese Konditionen. CLRB hatte gestern bei 2,77$ geschlossen und macht heute ein Offering zu 1,35$? 50% Discount?

https://seekingalpha.com/news/...ublic-offering-and-private-placement

 

 

1/10 RS

https://investor.cellectar.com/press-releases/...-stock-consolidation

 

Jetzt fehlt nur noch die Kapitalerhöhung... ;-)  

https://www.xm.com/research/markets/allNews/...d-cancer-drug-53643189  

https://www.globenewswire.com/news-release/2023/...ch-Foundation.html  

https://www.nasdaq.com/articles/...erapy-succeeds-in-late-stage-study  

https://d1io3yog0oux5.cloudfront.net/...Top_line_Data_from_WM_315.pdf

Preliminary Third Quarter 2023 Financial Highlights
Cash and Cash Equivalents:As of September 30, 2023, the company had cash and
cash equivalents of $19.0 million, compared to $19.9 million as of December 31, 2022.
During the third quarter, the company entered into a securities purchase agreement
with certain institutional investors for a private placement financing that is expected to
result in gross proceeds of up to $102.9 million, based upon achievement of certain
milestones. Current cash includes an initial funding of $22.2 million from the
transaction, net of commissions and fees. The company believes its cash on hand is
adequate to fund budgeted operations into the second quarter of 2024.
Research and Development Expense: R&D expense for the three months ended
September 30, 2023 was approximately $7.3 million, compared to approximately $5.4
million for the three months ended September 30, 2022. The overall increase in
research and development expense was primarily a result of an increase in WM pivotal
trial patient enrollment and expansion of the central nervous system lymphoma cohort
of the company’s Phase 2a basket trial in blood-b  

bezüglich Cash und Cashreichweite die letzten sind (andere habe ich nicht gefunden)dann müsste demnächst eine KE anstehen.